2024 Annual Report update Sydney, Australia, 4 October 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), notes that the Company’s securities are suspend from trading under Listing Rule 17.5 for the Company not lodging its full year financial statements by 30 September 2024. The Company advises that the release of its 2024 Annual Report has been delayed pending an announcement by the Company in relation to a proposed capital raise. The Company notes that its Appendix 4E and Preliminary Final Report were released on 30 August 2024. The Company anticipates a further announcement will be made on or before Friday 11 October 2024. Phillip Hains Joint Company Secretar
CHM Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)